{"id":13216,"date":"2023-10-07T20:54:00","date_gmt":"2023-10-07T12:54:00","guid":{"rendered":"https:\/\/flcube.com\/?p=13216"},"modified":"2024-11-17T20:58:06","modified_gmt":"2024-11-17T12:58:06","slug":"zhaoke-ophthalmology-completes-patient-enrollment-for-phase-iii-trials-of-tab014-and-epinastine","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=13216","title":{"rendered":"Zhaoke Ophthalmology Completes Patient Enrollment for Phase III Trials of TAB014 and Epinastine"},"content":{"rendered":"\n

Zhaoke Ophthalmology Ltd (HKG: 6622<\/a>), a former subsidiary of Lee\u2019s Pharmaceutical Holdings Ltd (HKG: 0950<\/a>), has announced the successful completion of patient enrollment for two separate Phase III clinical studies: one for TAB014 and another for epinastine, a generic version of Allergan\u2019s Elestat. This milestone underscores Zhaoke’s commitment to advancing ophthalmic therapies.<\/p>\n\n\n\n

TAB014: Targeting Neovascular Wet AMD<\/strong><\/p>\n\n\n\n

TAB014 is a recombinant anti-VEGF antibody being developed for the treatment of neovascular wet age-related macular degeneration (wAMD). The Phase III clinical study is randomized, double-blinded, and non-inferiority in design. Its primary objective is to evaluate baseline changes in best corrected visual acuity (BCVA) at week 52 among patients receiving TAB014 compared to those treated with Novartis\u2019s ranibizumab. This comprehensive study involves 488 patients across 60 centers, with Professor Chen Youxin from Beijing Union Medical College Hospital serving as the primary investigator.<\/p>\n\n\n\n

Epinastine: Addressing Seasonal Allergic Conjunctivitis<\/strong><\/p>\n\n\n\n

In addition, the efficacy and safety of epinastine will be evaluated in a multi-center, randomized, double-blinded, positive-controlled Phase III study targeting patients with seasonal allergic conjunctivitis. This study has successfully enrolled 266 patients across 14 centers, further highlighting Zhaoke’s robust pipeline in ophthalmology.<\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Zhaoke Ophthalmology Ltd (HKG: 6622), a former subsidiary of Lee\u2019s Pharmaceutical Holdings Ltd (HKG: 0950),…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[941,942,165,44,166],"class_list":["post-13216","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-hkg-0950","tag-hkg-6622","tag-lees-pharmaceutical","tag-ophthalmology","tag-zhaoke-ophthalmology"],"yoast_head":"\nZhaoke Ophthalmology Completes Patient Enrollment for Phase III Trials of TAB014 and Epinastine - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Zhaoke Ophthalmology Ltd (HKG: 6622), a former subsidiary of Lee\u2019s Pharmaceutical Holdings Ltd (HKG: 0950), has announced the successful completion of patient enrollment for two separate Phase III clinical studies: one for TAB014 and another for epinastine, a generic version of Allergan\u2019s Elestat. This milestone underscores Zhaoke's commitment to advancing ophthalmic therapies.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=13216\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Zhaoke Ophthalmology Completes Patient Enrollment for Phase III Trials of TAB014 and Epinastine\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=13216\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-10-07T12:54:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-17T12:58:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=13216#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=13216\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Zhaoke Ophthalmology Completes Patient Enrollment for Phase III Trials of TAB014 and Epinastine\",\"datePublished\":\"2023-10-07T12:54:00+00:00\",\"dateModified\":\"2024-11-17T12:58:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=13216\"},\"wordCount\":198,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"HKG: 0950\",\"HKG: 6622\",\"Lee's Pharmaceutical\",\"Ophthalmology\",\"Zhaoke Ophthalmology\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=13216#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=13216\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=13216\",\"name\":\"Zhaoke Ophthalmology Completes Patient Enrollment for Phase III Trials of TAB014 and Epinastine - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-10-07T12:54:00+00:00\",\"dateModified\":\"2024-11-17T12:58:06+00:00\",\"description\":\"Zhaoke Ophthalmology Ltd (HKG: 6622), a former subsidiary of Lee\u2019s Pharmaceutical Holdings Ltd (HKG: 0950), has announced the successful completion of patient enrollment for two separate Phase III clinical studies: one for TAB014 and another for epinastine, a generic version of Allergan\u2019s Elestat. This milestone underscores Zhaoke's commitment to advancing ophthalmic therapies.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=13216#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=13216\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=13216#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Zhaoke Ophthalmology Completes Patient Enrollment for Phase III Trials of TAB014 and Epinastine\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Zhaoke Ophthalmology Completes Patient Enrollment for Phase III Trials of TAB014 and Epinastine - Insight, China's Pharmaceutical Industry","description":"Zhaoke Ophthalmology Ltd (HKG: 6622), a former subsidiary of Lee\u2019s Pharmaceutical Holdings Ltd (HKG: 0950), has announced the successful completion of patient enrollment for two separate Phase III clinical studies: one for TAB014 and another for epinastine, a generic version of Allergan\u2019s Elestat. This milestone underscores Zhaoke's commitment to advancing ophthalmic therapies.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=13216","og_locale":"en_US","og_type":"article","og_title":"Zhaoke Ophthalmology Completes Patient Enrollment for Phase III Trials of TAB014 and Epinastine","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=13216","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-10-07T12:54:00+00:00","article_modified_time":"2024-11-17T12:58:06+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=13216#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=13216"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Zhaoke Ophthalmology Completes Patient Enrollment for Phase III Trials of TAB014 and Epinastine","datePublished":"2023-10-07T12:54:00+00:00","dateModified":"2024-11-17T12:58:06+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=13216"},"wordCount":198,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["HKG: 0950","HKG: 6622","Lee's Pharmaceutical","Ophthalmology","Zhaoke Ophthalmology"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=13216#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=13216","url":"https:\/\/flcube.com\/?p=13216","name":"Zhaoke Ophthalmology Completes Patient Enrollment for Phase III Trials of TAB014 and Epinastine - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-10-07T12:54:00+00:00","dateModified":"2024-11-17T12:58:06+00:00","description":"Zhaoke Ophthalmology Ltd (HKG: 6622), a former subsidiary of Lee\u2019s Pharmaceutical Holdings Ltd (HKG: 0950), has announced the successful completion of patient enrollment for two separate Phase III clinical studies: one for TAB014 and another for epinastine, a generic version of Allergan\u2019s Elestat. This milestone underscores Zhaoke's commitment to advancing ophthalmic therapies.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=13216#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=13216"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=13216#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Zhaoke Ophthalmology Completes Patient Enrollment for Phase III Trials of TAB014 and Epinastine"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/13216","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=13216"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/13216\/revisions"}],"predecessor-version":[{"id":13217,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/13216\/revisions\/13217"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=13216"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=13216"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=13216"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}